Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer

dc.contributor.authorCalik, Ilknur
dc.contributor.authorÇalık, Muhammet
dc.contributor.authorÖzercan, Hanifi İbrahim
dc.contributor.authorDagli, Adile Ferda
dc.contributor.authorArtaş, Gökhan
dc.contributor.authorTürken, Gülistan
dc.contributor.authorSarıkaya, Burcu
dc.date.accessioned2026-08-12T15:37:31Z
dc.date.issued2020
dc.departmentFırat Üniversitesi
dc.description.abstractObjective: Since colorectal cancers (CRC) are tumors with heterogeneous biological behavior, prediction of theirprognosis remains challenging. Caudal-related homeobox gene 2 (CDX2), which has important roles in the developmentand maintenance of intestines, is thought to have tumor suppressing effect on CRCs. The aim of this study was toinvestigate the prognostic significance of decreased-CDX2 expression.Method: This retrospective study included 224 patients diagnosed with CRC between 2009 and 2014. Paraffinized blocksof these patients were stained with CDX2 immunohistochemically and evaluated semiquantitatively.Results: Only 35 (15.6%) of 224 patients had low-CDX2 expression. Decrease in CDX2 expression was closely associatedwith classical prognostic parameters such as histopathologic type, histologic grade, lymph node metastasis, distantmetastasis, and TNM stage. Patients with decreased-CDX2 expression had more lymph node metastasis (p=0.013) andadvanced TNM stage (p=0.004) than those without decreased-expression. The mean survival was 53.0±0.89 months. Coxregression analysis showed that decreased-CDX2 expression was significantly related with overall survival (Univariateanalysis; hazard ratio: 0.09, 95% confidence interval: 0.05-0.16; p<0.001; Multivariate analysis; hazard ratio: 0.24, 95%confidence interval: 0.13-0.48; p<0.001) and disease-free survival (Univariate analysis; hazard ratio: 0.80, 95% confidenceinterval: 0.05-0.13; p<0.001; Multivariate analysis; hazard ratio: 0.15, 95% confidence interval: 0.08-0.25; p<0.001).Conclusion: Decreased CDX2 expression is significantly related with worse biological features and can be used as anindependent prognostic biomarker in patients with CRCs.
dc.identifier.doi10.5798/dicletip.706005
dc.identifier.endpage65
dc.identifier.issn1300-2945
dc.identifier.issn1308-9889
dc.identifier.issue1
dc.identifier.startpage57
dc.identifier.trdizinid370601
dc.identifier.urihttps://doi.org/10.5798/dicletip.706005
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/370601
dc.identifier.urihttps://hdl.handle.net/11508/35514
dc.identifier.volume47
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofDicle Tıp Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.tubitakinfo:eu-repo/grantAgreement/TUBITAK//
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260511
dc.subjectTıbbi Araştırmalar Deneysel
dc.subjectGenel ve Dahili Tıp
dc.subjectOnkoloji
dc.titleDecreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer
dc.typeArticle

Dosyalar